A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic ER+ Her2- Breast Cancer|Postmenopausal
Interventions: DRUG: Exemestane|DRUG: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|DRUG: Abiraterone acetate + Prednisone or Prednisolone
Sponsor: Janssen Research & Development, LLC